ClinicalTrials.gg
CompletedNCT03988374Updated Aug 23, 2021Results posted

Clinical Efficacy Evaluation of Three Dentifrices

A Phase 2 interventional study of Dentifrices in Gingival Inflammation and Bleeding and Dental Plaque, sponsored by Church & Dwight Company, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-08-23.

Sponsored by Church & Dwight Company, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Feb 2018, registered Apr 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
319
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Gingivitis with a site in Canada — 1 open to participants now, 2 under way, none of them phase 3. Gingivitis · Canada.

Enrollment
Largest of 22
319 · median 108
Started
2018
with 2 others
Phase 2
5 of 22
none open now
Registered
10th of 22
by date
Lead sponsor
3 of 22
Church & Dwight Company, Inc.

Among the 22 studies in Gingivitis with a site in Canada, this one has the largest enrollment, is one of 3 that started in 2018, is one of 5 in phase 2, and was the 10th registered.

Gingivitis

631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.

Browse Gingivitis studies →

Open to participants now

1 of the 22 studies in Gingivitis with a site in Canada is open now. Recruiting first, the newest first:

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 53 Gingivitis studies recruiting now, 15 (28%) set no upper age limit and 36 (68%) stop at 75 or younger; 11 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Gingivitis with a site in Canada, or all of them as a file.
02

Study summary

Clinical study to evaluate and compare the efficacy of two baking soda containing dentifrices, containing 20% and 35% baking soda, to a non-baking soda dentifrice for their ability to reduce gingivitis and plaque following 6-months of use.

03

Conditions studied

  • Gingival Inflammation and Bleeding
  • Dental Plaque
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have provided written prior to being entered into the study.
  • Be between 18 and 70 years of age, male or female.
  • Have at least eighteen (18) natural teeth with scorable facial and lingual surfaces as determined by the Examiner. Teeth that are grossly carious, orthodontically banded, exhibiting general cervical abrasion and/or enamel abrasion, or third molars will not be included in the tooth count.
  • Have a mean baseline plaque index score ≥ 1.95 as determined by the Soparkar Modification of the Turesky Modification of the Quigley-Hein Plaque Index (Pl).
  • Have a mean baseline gingival index score of ≥ l.70 and ≤ 3.0 as determined by the Modified Gingival Index (MGI).
  • Presence of ≥ 10 bleeding sites upon probing.
  • Agree not to have a dental prophylaxis or any other elective, non-emergency dental procedures any time during the study.
  • Agree to abstain from the use of chewing gum, mouth rinses, any toothpaste other than the study toothpaste, tooth whitening products (either professional or at home use) and all other oral hygiene other than the study procedures for the duration of the study.
  • Agree to refrain from all oral hygiene on the morning of each evaluation visit and to refrain from eating, drinking, and smoking for 4 hrs, prior to each evaluation visit.
  • Agree to comply with the conditions and schedule of the study.

Exclusion criteria

Exclusion Criteria:

  • Physical limitations or restrictions that might preclude normal tooth brushing.
  • Evidence of gross oral pathology, including widespread caries or chronic neglect, extensive restoration, preexisting gross plaque or soft or hard tissue tumor of the oral cavity.
  • Heavy supra- or subgingival calculus that might interfere with evaluations as determined by the Investigator/Examiner.
  • Evidence of major oral hard or soft tissue lesions or trauma at the baseline visit as determined by the Investigator/Examiner.
  • Conditions requiring antibiotic treatment prior to dental procedures.
  • History of uncontrolled diabetes or hepatic or renal disease, or other serious conditions or transmittable diseases, (e.g. cardiovascular disease, AIDS).
  • Subjects with grossly carious, fully crowned, or extensively restored teeth, orthodontic appliances, peri/oral piercings, or removable partial dentures.
  • Treatment with antibiotics within the 1-month period before the baseline examination, or a condition that is likely to require antibiotic treatment over the course of the trial.
  • Chronic treatment (2 weeks or more) with any medication known to affect periodontal status (including phenytoin, calcium antagonists, cyclosporine, coumarin, nonsteroidal anti-inflammatory drugs, and aspirin) within 1 month of the baseline examination. All other medications for chronic medical conditions must have been initiated at least 3 months before enrollment.
  • Have severe periodontal disease or being actively treated for periodontal disease.
  • Having history of early-onset periodontitis or acute necrotizing ulcerative gingivitis.
  • Concomitant periodontal therapy other than prophylaxis in the last 6 months.
  • Professional prophylaxis within 1 month prior to the baseline clinical evaluation.
  • Subjects who participated in a gingivitis study in the past month.
  • Daily use of chemotherapeutic antiplaque/antigingivitis products within the past 4 months.
  • History of significant adverse effects following use of oral hygiene products such as toothpastes and mouthrinses.
  • Subjects who are allergic to any ingredients in the test or control product, as listed on the IRB Safety Assessment.
  • Self-reported pregnancy and nursing since hormonal changes can exaggerate gingival response to dental plaque.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
319 participants (actual)

Study arms

  • Active comparator
    0% Baking Soda Dentifrice

    Drug: Dentifrices

  • Active comparator
    20% Baking Soda Dentifrice

    Drug: Dentifrices

  • Active comparator
    35% Baking Soda Dentifrice

    Drug: Dentifrices

Interventions

  • Dentifrice on plaque, gingivitis, and bleeding.

06

What researchers measure

Primary outcomes

  1. Mean Within-Treatment Whole-Mouth Score - Gingival Efficacy

    Mean Within-Treatment Whole-Mouth Score as measured by Gingival Index (0=absence of inflammation, 1=mild inflammation: slight change in color, little change in texture of any portion of but not the entire marginal or papillary gingival unit, 2=mild inflammation: slight change in color, little change in texture to entire marginal or papillary gingival unit, 3=moderate inflammation: glazing, redness, edema and/or hypertrophy of the marginal or papillary gingival unit, 4=severe inflammation: marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. The scale ranges from 0-4.

    Time frame: baseline, six weeks, 3 months and 6 months

  2. Mean Within-Treatment Whole-Mouth Score - Gingival Bleeding Efficacy

    Mean Within-Treatment Whole-Mouth Score as measured by Gingival Bleeding Index (0=absence of bleeding after 30 seconds, 1= bleeding observed after 30 seconds, 2= bleeding occurs instantly). The scale ranges from 0-2.

    Time frame: baseline, six week, three months, and six months

  3. Mean Within-Treatment Whole-Mouth Score - Plaque Efficacy

    Mean Within-Treatment Whole-Mouth Score as measured by Plaque Index (0=no visible plaque, 1=separate flecks of plaque at the cervical margin of the tooth, 2=a thin, continuous band of plaque (up to 1mm wide) at the cervical margin, 3= a band of plaque wider than 1 mm but covering less than one-third of the crown, 4=plaque covering at least one-third but less than two-thirds of the crown, 5= plaque covering two-thirds or more of the crown). The scale ranges from 0-5.

    Time frame: baseline, six weeks, three months, and six months

07

Results

Posted Aug 23, 2021

Participant flow

Participant flow — Overall Study
Milestone0% Baking Soda Dentifrice20% Baking Soda Dentifrice35% Baking Soda Dentifrice
Started104107108
Completed103105107
Not completed121

Outcome measures

PrimaryMean Within-Treatment Whole-Mouth Score - Gingival Efficacy

Mean Within-Treatment Whole-Mouth Score as measured by Gingival Index (0=absence of inflammation, 1=mild inflammation: slight change in color, little change in texture of any portion of but not the entire marginal or papillary gingival unit, 2=mild inflammation: slight change in color, little change in texture to entire marginal or papillary gingival unit, 3=moderate inflammation: glazing, redness, edema and/or hypertrophy of the marginal or papillary gingival unit, 4=severe inflammation: marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. The scale ranges from 0-4.

Time frame:
baseline, six weeks, 3 months and 6 months
Reported as:
Mean · units on a scale
Mean Within-Treatment Whole-Mouth Score - Gingival Efficacy
units on a scale0% Baking Soda Dentifrice20% Baking Soda Dentifrice35% Baking Soda Dentifrice
Baseline2.081 ± 0.0962.094 ± 0.1172.092 ± 0.106
6 weeks1.996 ± 0.1381.919 ± 0.1711.882 ± 0.174
3 months1.980 ± 0.1551.841 ± 0.1981.766 ± 0.229
6 months1.946 ± 0.1491.763 ± 0.2091.653 ± 0.256
PrimaryMean Within-Treatment Whole-Mouth Score - Gingival Bleeding Efficacy

Mean Within-Treatment Whole-Mouth Score as measured by Gingival Bleeding Index (0=absence of bleeding after 30 seconds, 1= bleeding observed after 30 seconds, 2= bleeding occurs instantly). The scale ranges from 0-2.

Time frame:
baseline, six week, three months, and six months
Reported as:
Mean · units on a scale
Mean Within-Treatment Whole-Mouth Score - Gingival Bleeding Efficacy
units on a scale0% Baking Soda Dentifrice20% Baking Soda Dentifrice35% Baking Soda Dentifrice
Baseline0.165 ± 0.0850.178 ± 0.1290.189 ± 0.114
6 weeks0.149 ± 0.0910.135 ± 0.1220.122 ± 0.081
3 months0.141 ± 0.0880.116 ± 0.1170.094 ± 0.067
6 months0.129 ± 0.0820.096 ± 0.1040.069 ± 0.053
PrimaryMean Within-Treatment Whole-Mouth Score - Plaque Efficacy

Mean Within-Treatment Whole-Mouth Score as measured by Plaque Index (0=no visible plaque, 1=separate flecks of plaque at the cervical margin of the tooth, 2=a thin, continuous band of plaque (up to 1mm wide) at the cervical margin, 3= a band of plaque wider than 1 mm but covering less than one-third of the crown, 4=plaque covering at least one-third but less than two-thirds of the crown, 5= plaque covering two-thirds or more of the crown). The scale ranges from 0-5.

Time frame:
baseline, six weeks, three months, and six months
Reported as:
Mean · units on a scale
Mean Within-Treatment Whole-Mouth Score - Plaque Efficacy
units on a scale0% Baking Soda Dentifrice20% Baking Soda Dentifrice35% Baking Soda Dentifrice
Baseline2.409 ± 0.2202.411 ± 0.2442.356 ± 0.240
6 weeks2.280 ± 0.2112.134 ± 0.2592.026 ± 0.227
3 months 3 months2.251 ± 0.2022.066 ± 0.2601.907 ± 0.265
6 months2.196 ± 0.1911.925 ± 0.2391.793 ± 0.287

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0% Baking Soda Dentifrice0/103 (0%)0/103 (0%)4/103 (3.9%)
20% Baking Soda Dentifrice0/105 (0%)0/105 (0%)17/105 (16.2%)
35% Baking Soda Dentifrice0/107 (0%)0/107 (0%)2/107 (1.9%)
Most frequent other events
Most frequent other events
Event0% Baking Soda Dentifrice20% Baking Soda Dentifrice35% Baking Soda Dentifrice
Primary discomfortsGeneral disorders1/10311/1050/107
Primary discomfortsGeneral disorders3/1031/1050/107
Primary discomfortsGeneral disorders0/1033/1052/107
Primary discomfortsGeneral disorders0/1032/1050/107

Baseline characteristics

Age, Continuous
Age, Continuous(Age)0% Baking Soda Dentifrice20% Baking Soda Dentifrice35% Baking Soda DentifriceTotal
Mean44.07 (18 to 70)47.50 (18 to 70)47.32 (18 to 70)46.3 (18 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)0% Baking Soda Dentifrice20% Baking Soda Dentifrice35% Baking Soda DentifriceTotal
Female757480229
Male28312786
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)0% Baking Soda Dentifrice20% Baking Soda Dentifrice35% Baking Soda DentifriceTotal
Count of participants———0
Region of Enrollment
Region of Enrollment(participants)0% Baking Soda Dentifrice20% Baking Soda Dentifrice35% Baking Soda DentifriceTotal
Canada103105107315
Gingvial Efficacy
Gingvial Efficacy(units on a scale)0% Baking Soda Dentifrice20% Baking Soda Dentifrice35% Baking Soda DentifriceTotal
Mean2.081 (0 to 4)2.094 (0 to 4)2.092 (0 to 4)2.089 (0 to 4)
Gingival Bleeding Efficacy
Gingival Bleeding Efficacy(units on a scale)0% Baking Soda Dentifrice20% Baking Soda Dentifrice35% Baking Soda DentifriceTotal
Mean0.165 (0 to 2)0.178 (0 to 2)0.189 (0 to 2)0.177 (0 to 2)
Plaque Efficacy
Plaque Efficacy(units on a scale)0% Baking Soda Dentifrice20% Baking Soda Dentifrice35% Baking Soda DentifriceTotal
Mean2.409 (0 to 5)2.411 (0 to 5)2.356 (0 to 5)2.4 (0 to 5)
08

Study locations

1 site
  • All Sum Research Center Ltd.
    Mississauga, Ontario L4W OC2, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Aug 2018, 6 months.

Results were first posted in Aug 2021, 2 years 11 months after primary completion.

Of 16 phase 2 interventional studies under Gingivitis, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 15. This study's 6 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2019
First posted
Jun 17, 2019
StartActual
Feb 22, 2018
Primary completionActual
Aug 24, 2018
CompletionActual
Aug 24, 2018
Results first posted
Aug 23, 2021
Last update
Aug 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03988374
Responsible party
Sponsor
First posted
Jun 17, 2019
Start date
Feb 22, 2018
Primary completion
Aug 24, 2018
Completion
Aug 24, 2018
Results posted
Aug 23, 2021
Last update
Aug 23, 2021

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dentifrices

Start the discussion